TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER).

How it works

TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.

What the body does with it

Metabolism	Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; insulin secretion increases in response to dextrose.
Excretion	The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Half-life	Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Protein binding	Not applicable; amino acids and dextrose do not bind to plasma proteins.
Volume of Distribution	Not applicable; distributes throughout total body water.
Bioavailability	Intravenous: 100% bioavailable.
Onset of Action	Intravenous: Immediate upon infusion; provides caloric and nitrogen substrate.
Duration of Action	Duration depends on infusion rate and metabolic demand; typically administered over 24 hours in parenteral nutrition.

Classification & Brands

Dosing & administration

Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.

Dosage form	INJECTABLE
Renal impairment	GFR >50 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 50% or monitor BUN and creatinine; GFR <10 mL/min: avoid unless on dialysis; adjust based on nitrogen balance and fluid status.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor ammonia; Child-Pugh C: avoid use due to risk of encephalopathy from amino acid load.
Pediatric use	Neonates and infants: initial 0.5-1 g amino acids/kg/day, increase gradually to 2-3 g/kg/day; dextrose initial 4-6 mg/kg/min, titrate up to 12-15 mg/kg/min; continuous infusion via central vein.
Geriatric use	Start at lower end of dose range (0.5-1 g amino acids/kg/day); monitor fluid and electrolyte balance closely; adjust for renal function and comorbidities; rate reduction may be needed due to decreased metabolic reserve.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER).

Breastfeeding	Not excreted into milk in significant amounts; ingredients are normal nutrients. Compatible with breastfeeding. M/P ratio not applicable.
Teratogenic Risk	Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose may cause fetal hyperinsulinemia and hypoglycemia if maternal glucose levels are high. Use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

None (not FDA-approved, but similar parenteral nutrition products carry warnings for metabolic complications, including hyperglycemia, hyperosmolar coma, and electrolyte imbalances; use in patients with severe renal or hepatic disease may require dose adjustments).

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to any component","Severe hyperglycemia or hyperosmolar state","Uncontrolled metabolic acidosis","Anuria or severe renal impairment (unless dialyzed)","Inborn errors of amino acid metabolism (e.g., maple syrup urine disease)","Severe hepatic insufficiency with encephalopathy"]

Clinical Precautions

Precautions

["Risk of hyperglycemia, hyperosmolar hyperglycemic state, and rebound hypoglycemia if infusion is stopped abruptly","Monitor serum electrolytes, blood urea nitrogen (BUN), glucose, and liver function tests regularly","Use with caution in patients with renal insufficiency (may require protein restriction), hepatic failure, or metabolic disorders (e.g., maple syrup urine disease)","Potential for infection and thrombophlebitis with central venous access","Do not administer if solution is discolored or contains particulate matter"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; insulin secretion increases in response to dextrose.
Excretion	The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Half-life	Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Protein binding	Not applicable; amino acids and dextrose do not bind to plasma proteins.
Volume of Distribution	Not applicable; distributes throughout total body water.
Bioavailability	Intravenous: 100% bioavailable.
Onset of Action	Intravenous: Immediate upon infusion; provides caloric and nitrogen substrate.
Duration of Action	Duration depends on infusion rate and metabolic demand; typically administered over 24 hours in parenteral nutrition.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	GFR >50 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 50% or monitor BUN and creatinine; GFR <10 mL/min: avoid unless on dialysis; adjust based on nitrogen balance and fluid status.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor ammonia; Child-Pugh C: avoid use due to risk of encephalopathy from amino acid load.
Pediatric use	Neonates and infants: initial 0.5-1 g amino acids/kg/day, increase gradually to 2-3 g/kg/day; dextrose initial 4-6 mg/kg/min, titrate up to 12-15 mg/kg/min; continuous infusion via central vein.
Geriatric use	Start at lower end of dose range (0.5-1 g amino acids/kg/day); monitor fluid and electrolyte balance closely; adjust for renal function and comorbidities; rate reduction may be needed due to decreased metabolic reserve.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER).

Breastfeeding	Not excreted into milk in significant amounts; ingredients are normal nutrients. Compatible with breastfeeding. M/P ratio not applicable.
Teratogenic Risk	Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose may cause fetal hyperinsulinemia and hypoglycemia if maternal glucose levels are high. Use only if clearly needed.